2015
Nephrogenic Systemic Fibrosis
LaChance A, Abu-Alfa A, Cowper S. Nephrogenic Systemic Fibrosis. 2015, 119-136. DOI: 10.1007/978-1-4939-2395-3_12.ChaptersNephrogenic systemic fibrosisMagnetic resonance angiographySystemic fibrosisNon-renal patientsOff-label useDiverse medical specialtiesMedication toxicityRenal diseasePathological featuresRenal populationRare conditionUnsuspected conditionsLong-term effectsNew toxicitiesGadolinium retentionResonance angiographyDisease causesTreatment climateNovel diseaseMedical specialtiesFibrosisDiseasePhysiciansPharmaceutical companiesToxicity
2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilanceDiagnosing nephrogenic systemic fibrosis in the post‐FDA restriction era
Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE, Roditi GH. Diagnosing nephrogenic systemic fibrosis in the post‐FDA restriction era. Journal Of Magnetic Resonance Imaging 2014, 41: 1268-1271. PMID: 24903851, DOI: 10.1002/jmri.24664.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosis
2013
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report
Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2013, 44: 173-180. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisGadolinium-based contrast agentsDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemEvent Reporting SystemRenal functionPediatric casesResearch RegistryContrast agentsFibrosisDuplicate reportingU.S. FoodSystematic searchReported numberRegistryChildrenReporting systemFAERSExposureReportAgentsMethodsWeCases
2012
Nephrogenic systemic fibrosis: concepts and perspectives
de Souza Machado Igreja A, de Carvalho Mesquita K, Cowper SE, Costa IM. Nephrogenic systemic fibrosis: concepts and perspectives. Anais Brasileiros De Dermatologia 2012, 87: 597-607. PMID: 22892775, DOI: 10.1590/s0365-05962012000400013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-based contrast agentsSystemic fibrosisNephrogenic systemic fibrosis casesCareful clinicopathological correlationEffective preventive methodsMagnetic resonance imagingContrast agentsRenal impairmentRenal functionClinicopathological correlationSkin changesProgressive conditionFibrosis casesVisceral organsKidney disordersResonance imagingPreventive methodsPatientsFibrosisDiseaseExposureAgentsRemissionNephrologistsLinking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)
Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). Journal Of General Internal Medicine 2012, 27: 1697-1703. PMID: 22692632, PMCID: PMC3509314, DOI: 10.1007/s11606-012-2098-1.ChaptersConceptsPure red cell aplasiaNephrogenic systemic fibrosisChronic kidney disease patientsSerious adverse drug reactionsKidney disease patientsRed cell aplasiaReye's syndromeNSF casesCell aplasiaDisease patientsSystemic fibrosisAdministration of aspirinDanish Medicines AgencyAdverse drug reactionsYears of identificationCKD patientsCounter medicationsDrug reactionsAdverse reactionsGadodiamide administrationObscure illnessPediatric useMedicines AgencyPatientsSyndrome
2011
Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations
Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiagnosis of NSFNephrogenic systemic fibrosisClinicopathological definitionNSF diagnosisWorkup recommendationsPrior clinical experienceClinicopathological presentationRenal diseaseHistopathological featuresRisk factorsStudy populationPrecise causationSystemic fibrosisClinical experienceAccurate diagnosisClinical expertiseDiagnostic standardHistopathological atlasDiagnosisGold standardMedical investigationsCompelling associationPhysiciansIndisputable linkContrast agents
2010
Nephrogenic systemic fibrosis
Braverman IM, Cowper S. Nephrogenic systemic fibrosis. F1000 Medicine Reports 2010, 2: 84. PMID: 21283650, PMCID: PMC3026615, DOI: 10.3410/m2-84.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRenal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDisease
2009
Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation
Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu‐Alfa A, Cowper SE, Bucala R, Gomer RH. Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging 2009, 30: 1284-1288. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNephrogenic systemic fibrosisSerum amyloid PFibrocyte differentiationDifferentiation of monocytesNSF patientsBlood mononuclear cellsHemodialysis patientsInterleukin-12Mononuclear cellsPurified monocytesFibroblast-like cellsFibrotic lesionsHealthy controlsSystemic fibrosisAmyloid PContrast agentsPatientsMonocytesDifferentiation inhibitorWiley-LissFibrocytesOmniscanDifferentiation protocolsCellsMRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction
Kuo P, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, Weinreb J, Cowper S. MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. Applied Radiology 2009, 22-33. DOI: 10.37549/ar1683.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNephrogenic systemic fibrosisNephrogenic Systemic Fibrosis and Other Scleroderma Mimickers
Perazella M, Pope J, Cowper S. Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers. 2009, 97-106. DOI: 10.1007/978-1-84800-934-9_11.ChaptersNephrogenic systemic fibrosisCases of NSFSystemic fibrosisDiagnosis of NSFRisk of NSFDose of gadoliniumUnderlying renal diseaseYellow scleral plaquesDermal dendritic cellsNormal kidney functionSystemic fibrosing disorderScar-like fibrosisFibrocyte-like cellsExtracutaneous diseaseSymmetrical edemaEosinophilic fasciitisRenal insufficiencyAntinuclear antibodiesDendritic cellsFibrosing disorderRenal diseaseSystemic sclerosisHistopathological featuresHistopathological findingsKidney function
2008
NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment
Knopp EA, Cowper SE. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment. Seminars In Dialysis 2008, 21: 123-128. PMID: 18226008, DOI: 10.1111/j.1525-139x.2007.00399.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsEarly recognitionSystemic fibrosisAcute kidney diseaseSignificant risk factorsInvolved extremityRenal dysfunctionRenal insufficiencyExtracorporeal photopheresisRenal functionMedical therapyMuscle weaknessKidney diseaseRisk factorsDistressing diseaseEarly treatmentPhysical therapyEffective treatmentEarly symptomsEarly signsPatientsBeneficial effectsFibrosisTherapyNephrogenic Systemic Fibrosis: An Overview
Cowper SE. Nephrogenic Systemic Fibrosis: An Overview. Journal Of The American College Of Radiology 2008, 5: 23-28. PMID: 18180005, DOI: 10.1016/j.jacr.2007.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisRenal diseaseSkin disordersFibrosisDisordersContrast agents
2007
Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders
Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis & Rheumatism 2007, 56: 3173-3175. PMID: 17907160, DOI: 10.1002/art.22926.Commentaries, Editorials and LettersNephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor
Moreno‐Romero J, Segura S, Mascaró JM, Cowper SE, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. British Journal Of Dermatology 2007, 157: 783-787. PMID: 17627792, DOI: 10.1111/j.1365-2133.2007.08067.x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisDevelopment of NSFRenal insufficiency patientsOnset of symptomsNephrogenic fibrosing dermopathyPossible aetiological factorsMagnetic resonance angiographyRenal diseaseCase seriesAetiological factorsSystemic fibrosisResonance angiographyFibrotic conditionsPatientsParamagnetic contrast agentHistory of useDiseaseContrast agentsAngiographyFibrosisDermopathyEtiologyGadoliniumSymptomsNephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure
Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. Clinical Journal Of The American Society Of Nephrology 2007, 2: 264-267. PMID: 17699423, DOI: 10.2215/cjn.03921106.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsGadolinium exposureIncidence of NSFSevere renal failurePopulation of patientsMajor risk factorOccurrence of NSFDevastating complicationESRD populationRenal failureSignificant morbidityRadiologic studiesRisk factorsSystemic fibrosisPopulation studiesESRDPatientsDisease developmentRecent reportsExposureContrast agentsRiskMorbidityComplications
2006
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2006, 56: 21-26. PMID: 17097388, DOI: 10.1016/j.jaad.2006.10.047.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNSF patientsSystemic fibrosisGadolinium-containing contrast materialSubset of patientsSoft tissueNumber of patientsPilot investigationTissues of patientsGadolinium-based contrastGadolinium-containing contrast agentsParaffin-embedded specimenNegative controlRenal insufficiencyDevelopment of diseasePathophysiologic mechanismsUnknown etiologyEpidemiologic associationPatientsContrast materialTissue residence timeSingle histological sectionTissue specimensBlocks of tissueDetection of gadoliniumNephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion In Rheumatology 2006, 18: 614-617. PMID: 17053507, DOI: 10.1097/01.bor.0000245725.94887.8d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisNephrogenic fibrosing dermopathyRenal insufficiencyClinical awarenessSystemic diseaseClinical spectrumTreatment optionsFibrogenic factorsEffective therapyFatal disorderEnigmatic disorderClinical reportsCardinal featuresFibrosisSpecific causesDisordersPathogenesisFibrocytesFuture studiesCauseRheumatologistsPatientsEtiopathogenesisRegistryEditorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients
DeHoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients. Seminars In Dialysis 2006, 19: 191-194. PMID: 16689966, DOI: 10.1111/j.1525-139x.2006.00152.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisCases of NSFNephrogenic fibrosing dermopathyScleroderma-like diseaseRenal insufficiencyRenal patientsNSF patientsNephrology professionalsPatientsNephrology literatureSoft tissueTissue remodelingWound repairFibrosisSkinSpecific cellsComorbiditiesDermopathyInsufficiencySymptomsDisease